During the 25-year period from 1972-1996, 360 episodes ofbacteremia occurred in 248 (45%) of a total of 548 patients with acute leukemia on our hematology ward, with the rate of occurrence remaining almost unchanged. Patients with acute nonlymphocytic leukemia, however, had a significant decrease in the incidence of bacteremia during the last 5-year period. Gram-negative bacilli decreased in relative frequency from 64% for the first 15-year period to 40% for the last 5-year period, whereas gram-positive cocci increased from 24%to 51%. Escherichia coli and Enterobacter cloacae somewhat decreased in frequency, whereascoagulase-negative staphylococci and streptococci had considerable increases. In contrast, Pseudomonasaeruginosa was isolated at a relatively constant frequency, forming one of the top two pathogens throughout the study period. Despite the shift toward gram-positive cocci, therefore, P. aeruginosa remains a key organism in considering the initial empiric antibiotic regimen and infection prevention during neutropenia.
Introduction
Bacteremia remains a frequent complication with serious morbidity and mortality in patients with acute leukemia undergoing intensive chemotherapy and/or hematopoietic stem cell transplantation (1, 2) . In many cancer centers, gram-positive cocci, mostly coagulase-negative staphylococci (CNS), now have virtually replaced enteric gram-negative bacilli as major pathogens (3, 4) . However, gram-negative bacteremia, particularly due to Pseudomonasaeruginosa still has a poor prognosis (5, 6) . Thus, the prevalence patterns for bacteremia pathogens play an important role in the choice of antibiotics for the initial empiric treatment of febrile patients with cancer. The present study reviews our experience with bacteremia complicating acute leukemia over the 25 years from 1972-1996, focusing on both the recent decrease in the frequency of bacteremia seen amongpatients with acute nonlymphocytic leukemia (ANLL)and the clinical significance ofP. aeruginosa in the face of preponderant gram-positive cocci.
Patients and Methods
Pa tients A total of 548 patients with acute leukemia [434 with ANLL and 1 14 with acute lymphocytic leukemia (ALL)] were admitted to and discharged from the Third Department of Medicine, Kanazawa University Hospital to undergo intensive chemo- CSF) (Fig. 1) . The rhG-CSF was administered mainly to patients with ALLas well as those with relapsed or refractory acute leukemia (7) . All but transplant patients were treated on one 40-bed hospital floor and exposed to similar potential environmental contaminants under routine hospital care. Transplant patients received total or selective intestinal decontamination in protected environments, often combined with rhG-CSF prophylaxis, until posttransplant neutrophil counts exceeded 500/nl (8, 9) .
Blood cultures Blood cultures were described elsewhere (1 aeruginosa. Streptococci also increased in frequency from 2% (5/228) to 9% (7/77) (X2=5.536, p<0.05). Moreover, enterococci were isolated atthe same frequency as E. coli [10% (8/77) each] during the last period. Thus, the top five pathogens found during the last period included enterococci and streptococci, both of which replaced K. pneumoniae and E. cloacae. Among the enterococci, Enterococcus faecium was morefrequently isolated than Enterococcus faecalis. S. aureus, although in small numbers, was also isolated at an increasing frequency, but most of the isolates proved to be methicillin-sensitive.
Discussion
Recent data from a Centers for Disease Control and Prevention survey disclosed that the percentage of primary bacteremia among all nosocomial infections increased from 7% between 1980and 1986to 13%between 1990and 1992 (10) . Incontrast, the present study showed that the percentage of patients with acute leukemia whodeveloped bacteremia remained almost unchanged during the past 25 years, although the incidence of bacteremia per 1,000 hospital admissions decreased by 108 episodes. This reduction in incidence cannot easily be disregarded, however, since the average incidence per 1 ,000 hospital admissions in city or university hospitals has been reported as Patients with ANLLhad a significant decrease in the incidence ofbacteremia in the last 5-year period, as contrasted with patients with ALL.This mayreflect the fact that recent progress in the treatment of ANLLhas somewhatsurpassed that in the management of ALL, particularly in adult patients (1 1, 12) . In 1992, the principle was set up that prednisolone should not be used for the treatment of ANLLin the AML-92protocol of the Japan Adult Leukemia Study Group (12) , which may have contributed to such a decrease in incidence. Moreover, the recent decrease in the rate of polymicrobial bacteremia was noted in the present series. This may be related to the fact that changed (14%-21%). Also at other cancer centers in Japan, the organism remains as a major pathogen of bacteremia, despite prophylaxis with oral polymyxin-B or ciprofloxacin (2, 6, 15) . This is contrary to the decreasing frequency of P. aeruginosa infection at manycancer centers in the United States and Europe (16, 17) . At the National Cancer Institute in USA, the frequency of P. aeruginosa bacteremia or infection inexplicably dropped to less than 1% of all episodes of fever and neutropenia in cancer patients in the last decade ( 16) . Thus, the reason for such a discrepancy remains to be defined. Although E. coli and K. pneumoniae usually originate in the alimentary canal (18) , P. aeruginosa is mostly acquired exogenously as a mode of infection (1) . Despite the use of newer (3-lactam drugs with antipseudomonal activity, such as ceftazidime and imipenem, P. aeruginosa bacteremia continued to occur at a relatively constant frequency on our hematology ward. Indeed, all P. aeruginosa isolates obtained during the last 5-year period proved susceptible to either of the drugs. Reducing the exogenous acquisition of the organism is, however, most urgent for infection prevention. P. aeruginosa bacteremia is still associated with considerable morbidity and mortality in neutropenic patients with cancer (2, 5, 6) . Thus the flexibility in the choice of empiric antibiotics maywell depend on the frequency ofP. aeruginosa infection (16) . On the other hand, the recent increase in the frequency of gram-positive bacteremia seems to justify the empiric use of vancomycin. In some randomized studies, however, no survival advantage was obtained from the addition of vancomycinto the current empiric regimens, such as ceftazidime plus amikacin (3, 19) . Despite the shift toward gram-positive cocci, therefore, p. aeruginosa remains a key organism in considering the initial empiric antibiotic regimen.
